501 related articles for article (PubMed ID: 1655284)
21. A novel mutation of the WT1 gene (a tumor suppressor gene for Wilms' tumor) in a patient with Denys-Drash syndrome.
Sakai A; Tadokoro K; Yanagisawa H; Nagafuchi S; Hoshikawa N; Suzuki T; Kohsaka T; Hasegawa T; Nakahori Y; Yamada M
Hum Mol Genet; 1993 Nov; 2(11):1969-70. PubMed ID: 8281164
[No Abstract] [Full Text] [Related]
22. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion.
Little MH; Williamson KA; Mannens M; Kelsey A; Gosden C; Hastie ND; van Heyningen V
Hum Mol Genet; 1993 Mar; 2(3):259-64. PubMed ID: 8388765
[TBL] [Abstract][Full Text] [Related]
23. Software and database for the analysis of mutations in the human WT1 gene.
Jeanpierre C; Béroud C; Niaudet P; Junien C
Nucleic Acids Res; 1998 Jan; 26(1):271-4. PubMed ID: 9399851
[TBL] [Abstract][Full Text] [Related]
24. Regulation of renal EGF receptor expression is normal in Denys-Drash syndrome.
Vicanek C; Ferretti E; Goodyer C; Torban E; Moffett P; Pelletier J; Goodyer P
Kidney Int; 1997 Sep; 52(3):614-9. PubMed ID: 9291179
[TBL] [Abstract][Full Text] [Related]
25. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X.
Heathcott RW; Morison IM; Gubler MC; Corbett R; Reeve AE
Hum Mutat; 2002 Apr; 19(4):462. PubMed ID: 11933209
[TBL] [Abstract][Full Text] [Related]
26. Dominant negative mutations in the Wilms tumour (WT1) gene cause Denys-Drash syndrome--proof that a tumour-suppressor gene plays a crucial role in normal genitourinary development.
Hastie ND
Hum Mol Genet; 1992 Aug; 1(5):293-5. PubMed ID: 1338905
[No Abstract] [Full Text] [Related]
27. Inactivation of the remaining allele of the WT1 gene in a Wilms' tumour from a WAGR patient.
Brown KW; Watson JE; Poirier V; Mott MG; Berry PJ; Maitland NJ
Oncogene; 1992 Apr; 7(4):763-8. PubMed ID: 1314370
[TBL] [Abstract][Full Text] [Related]
28. Genetic analysis of two female patients with incomplete Denys-Drash syndrome.
Ohta S; Ozawa T; Shiraga H; Fuse H
Endocr J; 2000 Dec; 47(6):683-7. PubMed ID: 11228042
[TBL] [Abstract][Full Text] [Related]
29. Exon skipping due to a mutation in a donor splice site in the WT-1 gene is associated with Wilms' tumor and severe genital malformations.
Schneider S; Wildhardt G; Ludwig R; Royer-Pokora B
Hum Genet; 1993 Jul; 91(6):599-604. PubMed ID: 8393425
[TBL] [Abstract][Full Text] [Related]
30. A novel WT1 gene mutation associated with wilms' tumor and congenital male genitourinary malformation.
Sakamoto J; Takata A; Fukuzawa R; Kikuchi H; Sugiyama M; Kanamori Y; Hashizume K; Hata JI
Pediatr Res; 2001 Sep; 50(3):337-44. PubMed ID: 11518820
[TBL] [Abstract][Full Text] [Related]
31. The third zinc finger of the WT1 gene is mutated in Wilms' tumour but not in a broad range of other urogenital tumours.
Quek HH; Chow VT; Tock EP
Anticancer Res; 1993; 13(5A):1575-80. PubMed ID: 8239537
[TBL] [Abstract][Full Text] [Related]
32. [Glomerulopathy in Denys-Drash syndrome. Case report of a model disease].
Stallmach T; Neuhaus TJ; Kösters R; Hailemariam S
Pathologe; 1998 May; 19(3):230-4. PubMed ID: 9648150
[TBL] [Abstract][Full Text] [Related]
33. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome.
Baird PN; Santos A; Groves N; Jadresic L; Cowell JK
Hum Mol Genet; 1992 Aug; 1(5):301-5. PubMed ID: 1338906
[TBL] [Abstract][Full Text] [Related]
34. The human sex-determining gene SRY is a direct target of WT1.
Hossain A; Saunders GF
J Biol Chem; 2001 May; 276(20):16817-23. PubMed ID: 11278460
[TBL] [Abstract][Full Text] [Related]
35. WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion.
Bardeesy N; Zabel B; Schmitt K; Pelletier J
Genomics; 1994 Jun; 21(3):663-4. PubMed ID: 7959750
[No Abstract] [Full Text] [Related]
36. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms.
Klamt B; Koziell A; Poulat F; Wieacker P; Scambler P; Berta P; Gessler M
Hum Mol Genet; 1998 Apr; 7(4):709-14. PubMed ID: 9499425
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations.
Schumacher V; Schärer K; Wühl E; Altrogge H; Bonzel KE; Guschmann M; Neuhaus TJ; Pollastro RM; Kuwertz-Bröking E; Bulla M; Tondera AM; Mundel P; Helmchen U; Waldherr R; Weirich A; Royer-Pokora B
Kidney Int; 1998 Jun; 53(6):1594-600. PubMed ID: 9607189
[TBL] [Abstract][Full Text] [Related]
38. A novel WT1 gene mutation in a newborn infant diagnosed with Denys-Drash syndrome.
Hakan N; Aydin M; Erdogan O; Cavusoglu YH; Aycan Z; Ozaltin F; Zenciroglu A; Apaydin S; Gunes R; Sahin G; Cinar G; Okumus N
Genet Couns; 2012; 23(2):255-61. PubMed ID: 22876585
[TBL] [Abstract][Full Text] [Related]
39. RNA binding by the Wilms tumor suppressor zinc finger proteins.
Caricasole A; Duarte A; Larsson SH; Hastie ND; Little M; Holmes G; Todorov I; Ward A
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7562-6. PubMed ID: 8755514
[TBL] [Abstract][Full Text] [Related]
40. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
Park S; Tomlinson G; Nisen P; Haber DA
Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
